American Journal of Ophthalmology
Volume 148, Issue 1 , Pages 38-42.e1 , July 2009

Vitreous Penetration of Orally Administered Famciclovir

  • Deborah Y. Chong

      Affiliations

    • W. K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan
    • ,
  • Mark W. Johnson

      Affiliations

    • W. K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan
    • Corresponding Author InformationInquiries to Mark W. Johnson, W. K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105
    • ,
  • Tony H. Huynh

      Affiliations

    • W. K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan
    • ,
  • Edward F. Hall

      Affiliations

    • W. K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan
    • ,
  • Grant M. Comer

      Affiliations

    • W. K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan
    • ,
  • Douglas N. Fish

      Affiliations

    • Department of Clinical Pharmacy, University of Colorado Denver, Aurora, Colorado

,Accepted 3 February 2009.

References 

  1. Holland GN. Standard diagnostic criteria for the acute retinal necrosis syndrome (Executive Committee of the American Uveitis Society). Am J Ophthalmol. 1994;117:663–667
  2. Fisher JP, Lewis ML, Blumenkranz M, et al. The acute retinal necrosis syndrome (Part 1: Clinical manifestations). Ophthalmology. 1982;89:1309–1316
  3. Blumenkranz MS, Culbertson WW, Clarkson JG, Dix R. Treatment of the acute retinal necrosis syndrome with intravenous acyclovir. Ophthalmology. 1986;93:296–300
  4. Chang S, Young LH. Acute retinal necrosis: An overview. Int Ophthalmol Clin. 2007;47:145–154
  5. Duker JS, Blumenkranz MS. Diagnosis and management of the acute retinal necrosis (ARN) syndrome. Surv Ophthalmol. 1991;35:327–343
  6. Muthiah MN, Michaelides M, Child CS, Mitchell SM. Acute retinal necrosis: a national population-based study to assess the incidence, methods of diagnosis, treatment strategies and outcomes in the United Kingdom. Br J Ophthalmol. 2007;91:1452–1455
  7. Palay DA, Sternberg P, Davis J, et al. Decrease in the risk of bilateral acute retinal necrosis by acyclovir therapy. Am J Ophthalmol. 1991;112:250–255
  8. Aizman A. Treatment of acute retinal necrosis syndrome. Drugs Today. 2006;42:545–551
  9. Figueroa MS, Garabito I, Gutierrez C, Fortun J. Famciclovir for the treatment of acute retinal necrosis (ARN) syndrome. Am J Ophthalmol. 1997;123:255–257
  10. Schulman JA, Peyman GA, Fiscella RG, et al. Parenterally administered acyclovir for viral retinitis associated with AIDS. Arch Ophthalmol. 1984;102:1750
  11. Aslanides IM, De Souza S, Wong DT, et al. Oral valacyclovir in the treatment of acute retinal necrosis syndrome. Retina. 2002;22:352–354
  12. Emerson GG, Smith JR, Wilson JD, et al. Primary treatment of acute retinal necrosis with oral antiviral therapy. Ophthalmology. 2006;113:2259–2261
  13. Savant V, Saeed T, Denniston A, Murray PI. Oral valganciclovir treatment of varicella zoster virus acute retinal necrosis. Eye. 2004;18:544–545
  14. Aizman A, Johnson MW, Elner SG. Treatment of acute retinal necrosis syndrome with oral antiviral medications. Ophthalmology. 2007;114:307–312
  15. Famvir (famciclovir) Prescribing Information. http://www.fda.gov/medwatch/SAFETY/2006/Feb_PI/Famvir_PI.pdfAccessed: November 17, 2008.
  16. Chakrabarty A, Tyring SK, Beutner K, Rauser M. Recent clinical experience with famciclovir—a “third generation” nucleoside prodrug. Antivir Chem Chemother. 2004;15:251–253
  17. Soul-Lawton J, Seaber E, On N, et al. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995;39:2759–2764
  18. Fletcher C, Bean B. Evaluation of oral acyclovir therapy. Drug Intell Clin Pharm. 1985;19:518–524
  19. Crumpacker C. The pharmacological profile of famciclovir. Semin Dermatol. 1996;15:14–26
  20. Valtrex (valacyclovir) Prescribing Information. http://www.fda.gov/medwatch/safety/2005/Nov_PI/Valtrex_PI.pdfAccessed: November 17, 2008.
  21. Huynh TH, Johnson MW, Comer GM, Fish DN. Vitreous penetration of orally administered valacyclovir. Am J Ophthalmol. 2008;145:682–686
  22. Balfour HH. Chapter 32: Acyclovir. In:  Peterson PK,  Verhoeft J editor. Antimicrobial Agents Annual 3. Amsterdam, The Netherlands: Elsevier; 1988;p. 345–360
  23. Pepose JS, Biron K. Antiviral sensitivities of the acute retinal necrosis syndrome virus. Curr Eye Res. 1987;6:201–205
  24. Höglund M, Ljungman P, Weller S. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother. 2001;47:855–861
  25. Oueghlani E, Baglivo E, Durakovic O, Safran AB. Varicella-zoster virus retinitis: successful evolution with a combination of antiviral therapies. Klin Monatsbl Augenheilkd. 2005;222:264–266
  26. Tran TH, Rozenberg F, Fillet AM, Bodaghi B. Diagnostic and therapeutic management of a severe acyclovir-resistant acute retinal necrosis in a young child. Graefes Arch Clin Exp Ophthalmol. 2005;243:266–268
  27. Teich SA, Cheung TW, Friedman AH. Systemic antiviral drugs used in ophthalmology. Surv Ophthalmol. 1992;37:19–53
  28. Hasegawa T, Kurokawa M, Yukawa TA, Horii M, Shiraki K. Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella zoster virus to PCV. Antiviral Res. 1995;27:271–279
  29. Safrin S, Phan L. In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrob Agents Chemother. 1993;37:2241–2243
  30. Talarico CL, Phelps WC, Biron KK. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella zoster virus isolated from patients with AIDS. J Virol. 1993;67:1024–1033

PII: S0002-9394(09)00107-X

doi: 10.1016/j.ajo.2009.02.010

American Journal of Ophthalmology
Volume 148, Issue 1 , Pages 38-42.e1 , July 2009

Article Tools